Mylan’s Glove-Integrity Warning Letter Fix Didn’t Extend to Adjacent Site
This article was originally published in The Gold Sheet
It’s a constant challenge for pharmaceutical manufacturers to ensure that quality problems identified at one site are fixed globally. In Mylan’s case, a problem with holes in gloves was resolved at one sterile manufacturing facility, but continued at another – even though it was right next door.
You may also be interested in...
Pfizer’s plan to acquire Hospira is part of a turnaround trend in which Big Pharma hopes its quality will rub off on the troubled generics injectables sector. The question is: Will it work?
Warning letter reveals agency found quality problems at Emergent BioSolutions’ Camden fill/finish plant during COVID-19 pandemic even as firm’s Bayview plant came under heightened scrutiny. Metal particulates appeared in vials as Camden plant and rest of Emergent’s CDMO network experienced sharp demand growth.
In the second part of In Vivo's series on mRNA manufacturing, we look at the technology behind the Moderna and Pfizer/BioNTech COVID-19 vaccines. Experts in the field are working on a variety of improvements that will enable quicker, cheaper, surer development and production of what could turn out to be a wide array of vaccines and therapeutics to be churned out by emerging mRNA platforms.